Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Parkinson's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Parkinson's
    TopAbstracts in Parkinson's 07/01/2009 - (DGNews)
    Long-Term Use of Prolonged-Release Ropinirole Well Tolerated by Patients With Early or Advanced Parkinson's Disease: Presented at ENS - (DGDispatch)
    Patients Treated With Preladenant for Parkinson's Disease Experience Reduced "Off" Time and Increased "On" Time With No Increase in Dyskinesia: Presented at MDS - (DGDispatch)
    Istradefylline Well Tolerated, Improves Motor Function During "On" State in Patients Receiving Levodopa for Parkinson's Disease: Presented at MDS - (DGDispatch)
    Zonisamide Safe and Effective in Long-Term Treatment of Parkinson's Disease: Presented at MDS - (DGDispatch)

    News archive

     Recent webcasts/CME - Parkinson's
      Initiating and Monitoring Pharmacotherapy in Patients with Parkinson's Disease
      Effective Management in Early Idiopathic Parkinson's Disease
      Case Studies in the Advancement of Parkinson's Disease
      Early Versus Delayed Diagnosis and Treatment of Parkinson's Disease: What You Need to Know
      Managing Parkinson's Disease with Continuous Dopaminergic Stimulation

      Webcasts/CME archive

       Recent cases - Parkinson's
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        Development of Parkinsonism Following Exposure to Aripiprazole: Two Case Reports
        Hypothermia with Osborn Waves in Parkinson's Disease
        HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
        Gliomatosis Cerebri Presenting as Rapidly Progressive Dementia and Parkinsonism in an Elderly Woman: A Case Report

        Cases archive
          




        my personal edition > parkinson's > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Addition of Rotigotine Has Benefits in Late-Stage Parkinson's Disease: Presented at AAN

          By Jill Stein

          BOSTON, MA -- May 3, 2007 -- Transdermal rotigotine at doses of 8 and 12 mg/day reduces "off" time in patients with advanced Parkinson's disease who are not optimally controlled with levodopa, researchers reported here at the American Academy of Neurology (AAN) 59th Annual Meeting.

          Rotigotine is a nonergolinic dopamine receptor agonist that is formulated as a patch for once-daily use.

          "Patients often experience immobility and other types of discomfort in the morning when they wake up, before their first oral dose of medication takes effect," said Peter A. LeWitt, MD, professor of neurology, Wayne State University, Milwaukee, Wisconsin.

          Dr. LeWitt discussed the phase 3 results on behalf of the SP Study Group in a presentation on May 3rd. "We found that patients who were treated with rotigotine were significantly more likely to be "on" when they awaken, compared to placebo-treated patients."

          The results are from a joint US-Canadian trial known as Prospective Randomized Evaluation of a new Formulation: Efficacy of Rotigotine (PREFER). In this trial, 351 patients with advanced idiopathic Parkinson's disease were randomized to placebo or 2 target doses of rotigotine (up to either 8 mg/24h or 12mg/24h) for up to 7 months.

          The trial included a 5-week titration phase followed by a 24-week maintenance phase. Rotigotine was added to stable levodopa treatment.

          Primary efficacy measures compared changes from baseline to the end of week 24 in the number of daily hours in the "off" state, and responder rates for subjects achieving 30% or greater reduction in "off" time.

          Compared with baseline, mean daily decreases in "off" time were 2.7 hours in patients who were treated with the 8-mg/24-hour dose and 2.1 hours with the 12-mg/24-hour dose. In the placebo group, duration of "off" time decreased by 0.9 hours (P <.001 and P <.003, respectively).

          Importantly, these improvements were sustained throughout the 24-week maintenance period.

          The study also found that the increase in "on time without troublesome dyskinesia" was greater for both rotigotine groups compared with placebo.

          Rotigotine was safe and well tolerated. The most common adverse events in the rotigotine groups were application site reactions, somnolence, nausea and vomiting, and dizziness.

          The study was sponsored by Schwarz Pharma.


          [Presentation title: Prospective Randomized Evaluation of a New Formulation: Efficacy of Rotigotine (PREFER). Abstract P06.022]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send